Updates in chronic cholestatic liver diseases: Indian expert recommendations for diagnosing and managing complex cases
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250286Keywords:
Cholestatic liver diseases, Primary biliary cholangitis, Primary sclerosing cholangitis, Non-invasive tests, Nonalcoholic fatty liver disease, Ursodeoxycholic acidAbstract
Cholestatic liver diseases (CCLDs) encompass hepatobiliary disorders leading to impaired bile secretion or reduced production, causing liver damage and fibrosis. Diagnosis relies on differentiation between hepatocellular and cholestatic diseases based on liver function tests (LFTs). Histological testing aids in detecting cholestasis-related alterations, crucial for identifying conditions like primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Non-invasive tests like FIB-4 and aspartate transaminase to platelet count ratio index (APRI), nonalcoholic fatty liver disease (NAFLD) fibrosis scoring, and elastography, offer alternatives to liver biopsy for fibrosis assessment. Evolving diagnostic procedures, such as endoscopic ultrasound-guided biopsies, complement traditional methods. Chronic cholestatic liver disease management includes treatment with ursodeoxycholic acid (UDCA). Alcoholic liver disease requires abstinence and nutrition therapy, while NAFLD management involves lifestyle changes and medications. Drug-induced liver injury necessitates prompt discontinuation and may involve UDCA, corticosteroids, and targeted therapies. Emerging treatments include farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, fibroblast growth factor 19 agonists, and immunosuppressive agents for conditions like PSC and nonalcoholic steatohepatitis. Ongoing evaluations explore various drug classes with newer therapeutic targets for these liver conditions.
Metrics
References
Ravindra BS, Lahoti D, Das K. Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study. Int J Sci Rep. 2023;9:17-27. DOI: https://doi.org/10.18203/issn.2454-2156.IntJSciRep20223372
Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents. Drugs. 2021;81:1181-92.
Parés A. Primary biliary cholangitis. Med Clin (Barc). 2018;151:242-9. DOI: https://doi.org/10.1016/j.medcle.2018.07.009
European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-72.
Lala V, Zubair M, Minter DA. Liver function tests. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 12 August 2024.
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112:18-35. DOI: https://doi.org/10.1038/ajg.2016.517
Ashraf J, Ali Khan M, Minhaj S, Khatti S, Aarij KM, Shehzad M, et al. Statins and abnormal liver function tests: Is there a correlation. Cureus. 2020;12(8):10145. DOI: https://doi.org/10.7759/cureus.10145
Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European association for the study of the liver (EASL), European association for the study of diabetes (EASD) and European association for the study of obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabetic Medicine. 2018;35(3):368-75. DOI: https://doi.org/10.1111/dme.13565
Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol. 2015;110:1298-304. DOI: https://doi.org/10.1038/ajg.2015.241
Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371-8. DOI: https://doi.org/10.1016/j.jhep.2019.03.033
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatolo. 2018;67:328-57. DOI: https://doi.org/10.1002/hep.29367
Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatol. 2011;53:325-35. DOI: https://doi.org/10.1002/hep.24013
Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J. 2011;101:477-80.
Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol. 2013;145:782-9. DOI: https://doi.org/10.1053/j.gastro.2013.06.057
Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2016;22:6663-72. DOI: https://doi.org/10.3748/wjg.v22.i29.6663
NAFLD fibrosis score. Available at: https://www.mdcalc.com. Accessed on 20th September 2023.
Alkhouri N, McCullough AJ. Non-invasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (NY). 2012;8:661-88.
Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-85. DOI: https://doi.org/10.1016/j.cld.2012.05.001
Kemp W, Roberts S. FibroScan® and transient elastography. Aust Fam Physician. 2013;42:468-71.
Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65:570-8. DOI: https://doi.org/10.1016/j.jhep.2016.04.023
Zaki, M, Hazem, M, Elsamman M. Shear wave elastography in assessment of liver stiffness and prediction of gastro-esophageal varices in patients with liver cirrhosis. Egypt J Radiol Nucl Med. 2019;50:1-9. DOI: https://doi.org/10.1186/s43055-019-0015-x
Ravindran S, Hancox SH, Howlett DC. Liver biopsy: past, present and future. Br J Hosp Med (Lond). 2016;77:90-5. DOI: https://doi.org/10.12968/hmed.2016.77.2.90
Shankar S, van Sonnenberg E, Silverman SG, Tuncali K. Interventional radiology procedures in the liver. Biopsy, drainage, and ablation. Clin Liver Dis. 2002;6:91-118. DOI: https://doi.org/10.1016/S1089-3261(03)00068-0
Miraglia R, Maruzzelli L, Caruso S, Milazzo M, Marrone G, Mamone G, et al. Interventional radiology procedures in adult patients who underwent liver transplantation. World J Gastroenterol, 2009;15:684-93. DOI: https://doi.org/10.3748/wjg.15.684
Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut. 2020;69:1382-403. DOI: https://doi.org/10.1136/gutjnl-2020-321299
Midia M, Odedra D, Shuster A, Midia R, Muir J. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. Diagn Interv Radiol. 2019;25:71-80. DOI: https://doi.org/10.5152/dir.2018.17525
Zensen S, Opitz MK, Grueneisen JS, Li Y, Haubold J, Steinberg HL, et al. Radiation exposure, organ and effective dose of CT-guided liver biopsy as a function of lesion depth and size. J Radiol Prot. 2022;42(3):80. DOI: https://doi.org/10.1088/1361-6498/ac7e80
Lu L, Chinese Society of Hepatology and Chinese Medical Association. Guidelines for the management of cholestatic liver diseases. J Clin Transl Hepatol. 2022;10:757-69. DOI: https://doi.org/10.14218/JCTH.2022.00147
de Vries EM, Wang J, Leeflang MM, Boonstra K, Weersma RK, Beuers UH, et al. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value. Liver Int. 2016;36:1867-75. DOI: https://doi.org/10.1111/liv.13110
Freedman BL, Danford CJ, Patwardhan V, Bonder A. Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis. J Clin Med. 2020;9(5):1449. DOI: https://doi.org/10.3390/jcm9051449
Galán AI, Muñoz ME, Palomero J, Moreno C, Jiménez R. Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment. J Physiol Biochem. 2000;56(3):189-200. DOI: https://doi.org/10.1007/BF03179786
Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic fatty liver disease and metabolic syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5:51-68. DOI: https://doi.org/10.1016/j.jceh.2015.02.006
Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307-18. DOI: https://doi.org/10.1038/nrgastro.2013.34
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85. DOI: https://doi.org/10.1056/NEJMoa0907929
Zhang W, Tang Y, Huang J, Hu H. Efficacy of ursodeoxycholic acid in non-alcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29:696-705. DOI: https://doi.org/10.21203/rs.2.15906/v1
Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol. 2014;2:74-9.
Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181-92. DOI: https://doi.org/10.1007/s40265-021-01545-7
Downloads
Published
How to Cite
Issue
Section
